Recordati SpAMilan, Italy
Disclosure information not submitted.
SAT-036 - Osilodrostat Treatment Outcomes Across Various Etiologies and Severities of Cushing'S Syndrome: LINC 7 Secondary Analysis
Saturday, June 13, 20269:30 AM - 4:30 PM CT
MON-015 - Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients with Hypertension Caused by Cushing'S Syndrome with Mean Urinary Free Cortisol ≤2X the Upper Limit of Normal: LINC CARE Study Design
Monday, June 15, 20269:00 AM - 2:00 PM CT
.jpg)
.jpg)